Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?

Naoki Ikegami, Michael Drummond, Shunichi Fukuhara, Shuzo Nishimura, George W. Torrance, François Schubert

研究成果: Article査読

20 被引用数 (Scopus)

抄録

The aging population and the increasing availability of new medical technologies, particularly pharmaceuticals, have led to growing pressure on governments worldwide to contain healthcare costs. Increasingly, economic evaluation is used to aid decisions on the reimbursement and formulary access of drugs, and pharmaceutical companies are often required to demonstrate the cost effectiveness of their products. Canada and the UK are examples of countries that have successfully incorporated mandatory requirements for economic evaluations into the decision-making process in healthcare. Japan faces cost-containment issues for its health and welfare system similar to those seen elsewhere in the world. Despite this, economic assessments are not currently used in the allocation of drug budgets. Reasons why economic evaluations for healthcare have not yet been used routinely in Japan include governmental approaches to healthcare cost containment, the pricing of pharmaceuticals, the organisation of the healthcare system, attitudes of the medical profession, and limited knowledge and expertise. However, small but encouraging steps are now being taken towards the introduction of economic evaluations in Japanese medicine.

本文言語English
ページ(範囲)1-7
ページ数7
ジャーナルPharmacoEconomics
20
SUPPL. 2
DOI
出版ステータスPublished - 2002

ASJC Scopus subject areas

  • 薬理学
  • 健康政策
  • 公衆衛生学、環境および労働衛生

フィンガープリント

「Why has the use of health economic evaluation in Japan lagged behind that in other developed countries?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル